# Pembrolizumab (MK-3475) in Hepatocellular Carcinoma

> **NCT02940496** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 15 (actual)

## Conditions studied

- BCLC Stage B Hepatocellular Carcinoma
- BCLC Stage C Hepatocellular Carcinoma
- Hepatitis C Infection
- Refractory Liver Carcinoma
- Stage III Hepatocellular Carcinoma AJCC v7
- Stage IIIA Hepatocellular Carcinoma AJCC v7
- Stage IIIB Hepatocellular Carcinoma AJCC v7
- Stage IIIC Hepatocellular Carcinoma AJCC v7
- Stage IV Hepatocellular Carcinoma AJCC v7
- Stage IVA Hepatocellular Carcinoma AJCC v7
- Stage IVB Hepatocellular Carcinoma AJCC v7

## Interventions

- **DRUG:** Elbasvir/Grazoprevir
- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT02940496
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-09
- **Primary completion:** 2023-08-09
- **Final completion:** 2023-08-09
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2025-07-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02940496

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02940496, "Pembrolizumab (MK-3475) in Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02940496. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*